Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Aveanna Healthcare Holdings ( (AVAH) ) has provided an announcement.
On February 27, 2026, Aveanna Healthcare Holdings Inc. announced that Class I director Robert M. Williams, Jr. resigned from its Board of Directors, effective immediately. The company stated that his departure was not due to any disagreement regarding Aveanna’s operations, policies or practices.
Before resigning, Williams served on Aveanna’s Nominating and Corporate Governance Committee, Compensation Committee, and Clinical Quality and Compliance Committee. His exit will require the company to adjust the composition and oversight responsibilities of these key board committees, potentially prompting near-term governance and leadership changes.
The most recent analyst rating on (AVAH) stock is a Hold with a $8.50 price target. To see the full list of analyst forecasts on Aveanna Healthcare Holdings stock, see the AVAH Stock Forecast page.
Spark’s Take on AVAH Stock
According to Spark, TipRanks’ AI Analyst, AVAH is a Neutral.
Overall score reflects weak financial foundation (high leverage and low profitability) and only modest technical momentum, partially offset by strong recent operating performance, raised guidance, and a mid-range valuation.
To see Spark’s full report on AVAH stock, click here.
More about Aveanna Healthcare Holdings
Aveanna Healthcare Holdings Inc. is a healthcare company that operates in the home- and community-based care sector, providing clinical and supportive services to patients. The company’s governance structure includes multiple board committees overseeing nominating and corporate governance, executive compensation, and clinical quality and compliance matters.
Average Trading Volume: 1,177,961
Technical Sentiment Signal: Buy
Current Market Cap: $1.47B
Learn more about AVAH stock on TipRanks’ Stock Analysis page.

